These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38342659)

  • 1. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
    Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
    Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
    Graham LS; Montgomery B; Cheng HH; Yu EY; Nelson PS; Pritchard C; Erickson S; Alva A; Schweizer MT
    PLoS One; 2020; 15(5):e0233260. PubMed ID: 32453797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
    Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
    Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.
    Lenis AT; Ravichandran V; Brown S; Alam SM; Katims A; Truong H; Reisz PA; Vasselman S; Nweji B; Autio KA; Morris MJ; Slovin SF; Rathkopf D; Danila D; Woo S; Vargas HA; Laudone VP; Ehdaie B; Reuter V; Arcila M; Berger MF; Viale A; Scher HI; Schultz N; Gopalan A; Donoghue MTA; Ostrovnaya I; Stopsack KH; Solit DB; Abida W
    Clin Cancer Res; 2024 Sep; 30(17):3894-3903. PubMed ID: 38949888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab.
    Bernard L; How JA; Patel S; Yates MS; Jazaeri A
    Gynecol Oncol; 2024 Jan; 180():139-145. PubMed ID: 38091773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatch repair deficiency and clinical implications in prostate cancer.
    Graham LS; Schweizer MT
    Prostate; 2022 Aug; 82 Suppl 1():S37-S44. PubMed ID: 35358351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification.
    Moufarrij S; Gazzo A; Rana S; Selenica P; Abu-Rustum NR; Ellenson LH; Liu YL; Weigelt B; Momeni-Boroujeni A
    Gynecol Oncol; 2024 Dec; 191():1-9. PubMed ID: 39276497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
    Amodio V; Lamba S; Chilà R; Cattaneo CM; Mussolin B; Corti G; Rospo G; Berrino E; Tripodo C; Pisati F; Bartolini A; Aquilano MC; Marsoni S; Mauri G; Marchiò C; Abrignani S; Di Nicolantonio F; Germano G; Bardelli A
    Cancer Cell; 2023 Jan; 41(1):196-209.e5. PubMed ID: 36584674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
    Konstantinopoulos PA; Luo W; Liu JF; Gulhan DC; Krasner C; Ishizuka JJ; Gockley AA; Buss M; Growdon WB; Crowe H; Campos S; Lindeman NI; Hill S; Stover E; Schumer S; Wright AA; Curtis J; Quinn R; Whalen C; Gray KP; Penson RT; Cannistra SA; Fleming GF; Matulonis UA
    J Clin Oncol; 2019 Oct; 37(30):2786-2794. PubMed ID: 31461377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
    Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
    JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report.
    Reed-Perino DE; Lai M; Yu EY; Schweizer MT
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
    Tucker MD; Zhu J; Marin D; Gupta RT; Gupta S; Berry WR; Ramalingam S; Zhang T; Harrison M; Wu Y; Healy P; Lisi S; George DJ; Armstrong AJ
    Cancer Med; 2019 Aug; 8(10):4644-4655. PubMed ID: 31270961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case report.
    Padovan M; Caccese M; Zagonel V; Lombardi G
    Anticancer Drugs; 2021 Feb; 32(2):218-221. PubMed ID: 33395066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
    Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
    Yu EY; Berry WR; Gurney H; Retz M; Conter HJ; Laguerre B; Fong PCC; Ferrario C; Todenhöfer T; Gravis G; Piulats JM; Emmenegger U; Shore ND; Romano E; Mourey L; Li XT; Poehlein CH; Schloss C; Appleman LJ; de Bono JS
    Eur Urol Oncol; 2024 Jun; 7(3):509-518. PubMed ID: 37940446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch repair deficiency as a prognostic factor in mucinous colorectal cancer.
    Andrici J; Farzin M; Sioson L; Clarkson A; Watson N; Toon CW; Gill AJ
    Mod Pathol; 2016 Mar; 29(3):266-74. PubMed ID: 26769140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months.
    Shimizu K; Sano T; Mizuno K; Sunada T; Makita N; Hagimoto H; Goto T; Sawada A; Fujimoto M; Ichioka K; Ogawa O; Kobayashi T; Akamatsu S
    Cold Spring Harb Mol Case Stud; 2022 Jun; 8(4):. PubMed ID: 35487690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
    Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
    JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.